Kopran Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹135Cr
- −3% YoY
- −21.5% QoQ
- Net profit
- ₹7Cr
- −32.9% YoY
- −23% QoQ
- Margin
- 10.45%
- −2.6 pp YoY
- +0.5 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q1 FY26 key numbers
- Revenue
- Year-on-year change in revenue: Slight decrease (Rs. 13,522 Lakhs vs Rs. 13,944 Lakhs).
As stated in Kopran Ltd's Q1 FY26 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5). Q1 FY 2025-26 EBITDA: Rs. 1,413 Lakhs (Page 5).
From Kopran Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5)
- Q1 FY 2024-25 revenue: Rs. 13,944 Lakhs (Page 5)
- Year-on-year change in revenue: Slight decrease (Rs. 13,522 Lakhs vs Rs. 13,944 Lakhs)
- Formulations Q1 FY 2025-26 revenue: Rs. 5,078 Lakhs; FY 2024-25 revenue: Rs. 26,249 Lakhs (Page 10)
- APIs Q1 FY 2025-26 revenue: Rs. 8,303 Lakhs; FY 2024-25 revenue: Rs. 35,881 Lakhs (Page 8)
2 more points from Kopran Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Strategic imperatives (Page 15) mention capacity expansion and setting up an API and R&D facility at Panoli.
- The focus is on capacity expansion to develop niche, high-value/high-volume APIs and intermediates.
- Emphasis on compliance with global regulatory standards.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Kopran Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 135 | 139 | -3% | 172 | -21.5% |
| Operating profit (EBITDA) | 14 | 18 | -22.2% | 17 | -17.3% |
| Operating margin | 10.45% | 13.02% | -2.6 pp | 9.92% | +0.5 pp |
| Profit before tax | 10 | 15 | -32.9% | 14 | -27.9% |
| Net profit (PAT) | 7 | 11 | -32.9% | 10 | -23% |
| EPS (₹) | 1.54 | 2.30 | -33% | 2.01 | -23.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q1 FY26 results?
Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5). Q1 FY 2025-26 EBITDA: Rs. 1,413 Lakhs (Page 5).
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Strategic imperatives (Page 15) mention capacity expansion and setting up an API and R&D facility at Panoli.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
